A Phase 4 interventional study of Rifaximin and Lactulose in Hepatic Encephalopathy and Cirrhosis, sponsored by Bausch Health Americas, Inc.. Completed at 43 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-09.
Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing rifaximin in Hepatic Encephalopathy — 3 open to participants now, 3 under way, none of them phase 3. Rifaximin · Hepatic Encephalopathy.
Among the 18 studies testing rifaximin in Hepatic Encephalopathy, this one is the 5th largest by enrollment, is one of 4 that started in 2013, is one of 8 in phase 4, and was the 9th registered.
225 studies on the registry are indexed under Hepatic Encephalopathy; 53 are open to participants now.
Browse Hepatic Encephalopathy studies →3 of the 18 studies testing rifaximin in Hepatic Encephalopathy are open now, in 4 countries. Recruiting first, the newest first:
Post Graduate Institute of Medical Education and Research, Chandigarh · Sites in India
Ages 18–65
Sun Yat-sen University · Sites in China
Ages 18–70
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Belgium, Netherlands
Ages 18–80
By country, each count listing its studies:
Rifaximin: first FDA approval 2004 (XIFAXAN). What it is approved for, and how studies give it, is on its page →
Of the 30 Hepatic Encephalopathy studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2013.
This study's enrollment of 222 is above the median of 60 across 154 interventional studies indexed under Hepatic Encephalopathy.
Median enrollment 94 across the 18 interventional studies. Of the 13 that completed or were terminated, 7 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under Bausch Health Americas, Inc., one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
Bausch Health Companies Inc. has 7 studies filed under Hepatic Encephalopathy — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing rifaximin in Hepatic Encephalopathy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate if rifaximin alone or rifaximin plus lactulose delays the onset of hepatic encephalopathy (HE) in participants with cirrhosis who have had a previous episode of HE.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive rifaximin 550 milligrams (mg) tablet orally twice daily (BID) for 24 weeks.
Drug: Rifaximin
Participants will receive rifaximin 550 mg tablet orally BID with lactulose solution for 24 weeks. Lactulose dose will be self-titrated by the participant to produce 2 to 3 soft stools per day.
Drug: Rifaximin · Drug: Lactulose
Number of Participants Reporting a First Breakthrough HE Episode
A breakthrough HE episode was defined as an increase of the Conn score to Grade greater than or equal to (≥) 2 (ie, 0 or 1 to ≥ 2). Conn score is widely used as a measure of mental state in HE. The scale used in Conn scoring system include: Grade 0=No personality or behavioral abnormality; Grade 1=Trivial lack of awareness, euphoria, or anxiety; shortened attention span, impairment of addition or subtraction; Grade 2=Lethargy, disorientation for time, obvious personality change, inappropriate behaviour; Grade 3=Somnolence to semi-stupor, responsive to stimuli, confused, gross disorientation, bizarre behaviour; Grade 4=Coma, unable to test mental state. The time to the first breakthrough HE episode was defined as the duration between the date of first dose of study drug and the date of first breakthrough HE episode. Number of participants reporting a first breakthrough HE episode during randomization to Month 6 is presented.
Time frame: From randomization (Day 1) up to Day 170
Number of Participants Who Were Hospitalized Due to HE Episode
An HE-related hospitalization was defined as a hospitalization directly resulting from HE, or when HE events occurred during hospitalization. The time to first HE-related hospitalization was defined as the duration between the date of first dose of study drug and the date of first HE-related hospitalization. Number of participants who were hospitalized due to HE episode during randomization to Month 6 is presented.
Time frame: From randomization (Day 1) up to Day 170
Number of Participants Who Died Due to Any Reason
Time frame: From randomization (Day 1) up to end of study (Day 186)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. TEAE was defined as an AE that occurred from first dose of study drug until last dose of study drug plus 5 days (for non-fatal AEs) or plus 30 days (for fatal AEs).A summary of non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
Time frame: From randomization (Day 1) up to end of study (Day 186)
Change From Baseline in Total Chronic Liver Disease Questionnaire (CLDQ) Score at Day 170
CLDQ was used to measure health-related quality of life. CLDQ includes 29 items in the following 6 domains: abdominal symptoms (3 items), fatigue (5 items), systemic symptoms (5 items), activity (3 items), emotional function (8 items), and worry (5 items). All items were measured on a 7-point Likert scale, ranging from 0 to 6 with higher values indicating better quality of life. Each domain score of CLDQ was calculated as the mean of the responses of items in that domain. Overall CLDQ score was obtained by adding scores for each item and dividing by the total number of items. Overall CLDQ score ranged from 0 (most impairment) to 6 (least impairment) with higher scores indicating better quality of life. If at least half of the items were non-missing for a domain, mean values of the non-missing items for that domain were used as imputed values for missing values. If more than half of the items in a domain were missing, no values were imputed and domain score was considered as missing.
Time frame: Baseline, Day 170
Change From Baseline in Critical Flicker Frequency (CFF) at Day 170
The critical flicker frequency (CFF), a validated assessment of neurological function was assessed using a specialized CFF instrument. The CFF is the frequency at which the participant observes a constant light transition to a flickering light and was measured in Hertz. The CFF was measured on a continuous scale and was the mean of 8 separate fusion-to-flicker transition tests performed in rapid succession. Increases in CFF results represent improvement in neurological function in participants with HE.
Time frame: Baseline, Day 170
| Milestone | Rifaximin 550 mg BID | Rifaximin 550 mg BID + Lactulose |
|---|---|---|
| Started | 113 | 109 |
| Received at least 1 dose of study drug | 113 | 108 |
| Completed | 69 | 79 |
| Not completed | 44 | 30 |
| Withdrew: Adverse event | 6 | 4 |
| Withdrew: He breakthrough | 26 | 13 |
| Withdrew: Liver transplant | 2 | 0 |
| Withdrew: Lost to follow-up | 2 | 5 |
| Withdrew: Withdrawal by subject | 5 | 7 |
| Withdrew: Other than specified | 3 | 1 |
A breakthrough HE episode was defined as an increase of the Conn score to Grade greater than or equal to (≥) 2 (ie, 0 or 1 to ≥ 2). Conn score is widely used as a measure of mental state in HE. The scale used in Conn scoring system include: Grade 0=No personality or behavioral abnormality; Grade 1=Trivial lack of awareness, euphoria, or anxiety; shortened attention span, impairment of addition or subtraction; Grade 2=Lethargy, disorientation for time, obvious personality change, inappropriate behaviour; Grade 3=Somnolence to semi-stupor, responsive to stimuli, confused, gross disorientation, bizarre behaviour; Grade 4=Coma, unable to test mental state. The time to the first breakthrough HE episode was defined as the duration between the date of first dose of study drug and the date of first breakthrough HE episode. Number of participants reporting a first breakthrough HE episode during randomization to Month 6 is presented.
| Participants | Rifaximin 550 mg BID | Rifaximin 550 mg BID + Lactulose |
|---|---|---|
| Number of Participants Reporting a First Breakthrough HE Episode | 28 | 15 |
An HE-related hospitalization was defined as a hospitalization directly resulting from HE, or when HE events occurred during hospitalization. The time to first HE-related hospitalization was defined as the duration between the date of first dose of study drug and the date of first HE-related hospitalization. Number of participants who were hospitalized due to HE episode during randomization to Month 6 is presented.
| Participants | Rifaximin 550 mg BID | Rifaximin 550 mg BID + Lactulose |
|---|---|---|
| Number of Participants Who Were Hospitalized Due to HE Episode | 23 | 14 |
| Participants | Rifaximin 550 mg BID | Rifaximin 550 mg BID + Lactulose |
|---|---|---|
| Number of Participants Who Died Due to Any Reason | 2 | 2 |
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. TEAE was defined as an AE that occurred from first dose of study drug until last dose of study drug plus 5 days (for non-fatal AEs) or plus 30 days (for fatal AEs).A summary of non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
| Participants | Rifaximin 550 mg BID | Rifaximin 550 mg BID + Lactulose |
|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 99 | 81 |
CLDQ was used to measure health-related quality of life. CLDQ includes 29 items in the following 6 domains: abdominal symptoms (3 items), fatigue (5 items), systemic symptoms (5 items), activity (3 items), emotional function (8 items), and worry (5 items). All items were measured on a 7-point Likert scale, ranging from 0 to 6 with higher values indicating better quality of life. Each domain score of CLDQ was calculated as the mean of the responses of items in that domain. Overall CLDQ score was obtained by adding scores for each item and dividing by the total number of items. Overall CLDQ score ranged from 0 (most impairment) to 6 (least impairment) with higher scores indicating better quality of life. If at least half of the items were non-missing for a domain, mean values of the non-missing items for that domain were used as imputed values for missing values. If more than half of the items in a domain were missing, no values were imputed and domain score was considered as missing.
| units on a scale | Rifaximin 550 mg BID | Rifaximin 550 mg BID + Lactulose |
|---|---|---|
| Baseline | 4.13 ± 1.110 | 4.26 ± 1.197 |
| Change at Day 170 | 0.29 ± 0.860 | 0.08 ± 1.055 |
The critical flicker frequency (CFF), a validated assessment of neurological function was assessed using a specialized CFF instrument. The CFF is the frequency at which the participant observes a constant light transition to a flickering light and was measured in Hertz. The CFF was measured on a continuous scale and was the mean of 8 separate fusion-to-flicker transition tests performed in rapid succession. Increases in CFF results represent improvement in neurological function in participants with HE.
| hertz | Rifaximin 550 mg BID | Rifaximin 550 mg BID + Lactulose |
|---|---|---|
| Baseline | 35.14 ± 7.767 | 34.64 ± 7.290 |
| Change at Day 170 | 1.09 ± 7.266 | 2.10 ± 6.699 |
Collected over From randomization (Day 1) up to end of study (Day 186). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rifaximin 550 mg BID | — | 43/113 (38.1%) | 68/113 (60.2%) |
| Rifaximin 550 mg BID + Lactulose | — | 35/108 (32.4%) | 53/108 (49.1%) |
| Event | Rifaximin 550 mg BID | Rifaximin 550 mg BID + Lactulose |
|---|---|---|
| Hepatic encephalopathyNervous system disorders | 21/113 | 10/108 |
| AscitesGastrointestinal disorders | 2/113 | 7/108 |
| Renal failure acuteRenal and urinary disorders | 6/113 | 3/108 |
| AnaemiaBlood and lymphatic system disorders | 5/113 | 1/108 |
| Urinary tract infectionInfections and infestations | 1/113 | 4/108 |
| CellulitisInfections and infestations | 3/113 | 1/108 |
| Supraventricular tachycardiaCardiac disorders | 0/113 | 2/108 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/113 | 2/108 |
| Peritonitis bacterialInfections and infestations | 2/113 | 2/108 |
| PneumoniaInfections and infestations | 1/113 | 2/108 |
| Event | Rifaximin 550 mg BID | Rifaximin 550 mg BID + Lactulose |
|---|---|---|
| Oedema peripheralGeneral disorders | 19/113 | 15/108 |
| ConstipationGastrointestinal disorders | 18/113 | 9/108 |
| NauseaGastrointestinal disorders | 16/113 | 11/108 |
| FatigueGeneral disorders | 16/113 | 9/108 |
| InsomniaPsychiatric disorders | 13/113 | 15/108 |
| DiarrhoeaGastrointestinal disorders | 5/113 | 13/108 |
| Urinary tract infectionInfections and infestations | 12/113 | 5/108 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 9/113 | 11/108 |
| Pruritus generalisedSkin and subcutaneous tissue disorders | 11/113 | 6/108 |
| AscitesGastrointestinal disorders | 7/113 | 10/108 |
Intent-to-treat (ITT) population included all randomized participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Rifaximin 550 mg BID | Rifaximin 550 mg BID + Lactulose | Total |
|---|---|---|---|
| Mean | 58.1 ± 9.51 | 58.8 ± 9.49 | 58.4 ± 9.49 |
| Sex: Female, Male(Participants) | Rifaximin 550 mg BID | Rifaximin 550 mg BID + Lactulose | Total |
|---|---|---|---|
| Female | 44 | 38 | 82 |
| Male | 69 | 70 | 139 |
| Lactulose Usage Prior to First Dose(Participants) | Rifaximin 550 mg BID | Rifaximin 550 mg BID + Lactulose | Total |
|---|---|---|---|
| Yes | 100 | 100 | 200 |
| No | 13 | 8 | 21 |
Ran from Jan 2013 to primary completion in Dec 2014, 23 months.
Results were first posted in Sep 2019, 4 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rifaximin
Bausch Health Americas, Inc. →